Nicola Davies, PhD

Big data is on the precipice of revolutionizing multiple sclerosis knowledge and treatment.

Digital biomarkers offer promise to revolutionize the diagnosis and treatment of Alzheimer disease via our increasing ability to gather active and passive data.

Addressing sleep apnea at a physiological level may reasonably be more effective and have fewer adverse effects than more traditional treatment modalities that may only target one mechanism.

Could expanding insights into the pathophysiology of autoimmune epilepsy offer seizure-free hope for patients?

Biomarkers in the cerebrospinal fluid and blood could hold the key to early diagnosis of Alzheimer disease.

Will ethical considerations and lack of consent stand in the way of thoroughly exploring the potential of this nondrug therapy?

A greater understanding of the role of the immune system in movement disorders may illuminate a path to treatments that target the central causes of disease.

Bogged down by a decades-long chase for a common pathology, investigators exploring alternative and complimentary theories are pushing to extend their time in the spotlight.

The implementation of focused ultrasound has been practice changing in tremor, but the various arenas in which this technology can be used opens up new treatment avenues for a range of neurological disorders.

Preclinical trials and success stories suggest that much is riding on vector-based therapies for the treatment of rare neurological conditions.